Day 2 – Saturday, September 20, 2008


(Download Full Agenda as PDF)Day 1 Agenda

7:00-8:00

Breakfast

8:00-8:05

House Business

ANTIBODIES AND RECEPTOR TARGETED THERAPIES
Moderators: Pier Luigi Zinzani, MD, PhD; Nam H. Dang, MD, PhD

8:05-8:20

Alemtuzumab (anti-CD52)

Pierluigi Porcu, MD

8:20-8:35

Iratumumab (anti-CD30)

Lauren C. Pinter-Brown, MD
8:35-8:50 HuMax-CD4 (anti-CD4)

Bertrand Coiffier, MD
8:50-9:05 Anti-CD2 John E. Janik, MD
9:05-9:20 Anti-Tac, Pseudotoxins, and Other Single-chair Antibody-based Therapies

Robert Kreitman, MD
9:20-9:35 Ontak in Refractory PTCL Nam H. Dang, MD, PhD
9:35-9:50 Treatment of Angioimmunoblastic T-cell Lymphomas with Cyclosporine, Rituximab

Ranjana Advani, MD
9:50-10:05 Discussion
10:05-10:20 Break

NOVEL APPROACHES
Moderators: Ranjana Advani, MD; Owen A. O’Connor, MD, PhD
10:20-10:35 Using Animal Models to Develop Novel Therapies

Owen A. O’Connor, MD, PhD
10:35-10:50 Role of Nucleoside Analogs in PTCL Varsha V. Gandhi, PhD
10:50-11:05 Gemcitabine and Velcade

Pier Luigi Zinzani, MD, PhD
11:05-11:20 Clinical Applications of HDAC Inhibitors Steven M. Horwitz, MD
11:20-11:35 Novel Folate Analogs Owen A. O’Connor, MD, PhD
11:35-11:50 Signal Transduction Inhibitors Steven T. Rosen, MD
11:50-12:05 New Drugs in Development for PTCL Bruce D. Cheson, MD
12:05-12:20 Discussion
12:20-1:30 Lunch

INTERNATIONAL T-CELL COLLABORATIONS – What are the Current Efforts and Next Steps?
Moderators: Emanuele Zucca, MD; Francine M. Foss, MD; Pier Luigi Zinzani, MD, PhD
1:30-1:45 Efforts to Establish an International T-cell Consortium

Julie M. Vose, MD
1:45-2:00 T-cell Lymphoma Tissue Bank Collaboration Pier Paolo Piccaluga, MD, PhD
2:00-2:15 US Registry and Clinical Trials Collaborations

Ranjana Advani, MD
2:15-2:30 Where Do We Go From Here?

Emanuele Zucca, MD
2:30-2:45 Discussion

SUMMARY AND PLANS FOR 2009 MEETING
Moderators: Francine M. Foss, MD; Pier Luigi Zinzani, MD, PhD
2:45-2:55 Adjournment

(Download Full Agenda as PDF)Back to Top